Peptides DB
Research-centric peptide and protocol reference hub

MOTS-C record · updated 18h ago

Metabolic & appetiteHealing & recoveryGrade A · human clinicalResearch use only
All 29 studiesJump to the evidenceCompare
What is MOTS-C used for?

MOTS-C is a mitochondrial-derived peptide that has garnered attention for its potential roles in metabolic regulation and cellular stress responses. Emerging research suggests it may have implications in various health conditions, including cardiovascular diseases and placental function.

How it works: Mitochondrial-derived peptide; AMPK activation / metabolic regulation

Primarily researched for · Metabolic & appetiteRoute · Subcutaneous injection (research use)

Development stage

where MOTS-C sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 117 registered trials. It describes the research record, not a recommendation.

Identity
NameMOTS-C
Chain length—
Molecular weight2,174.6 Da
FormulaC101H152N28O22S2
Structure typeNot established
ClassMetabolic
Research levelEmerging
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 146675088. No verified residue count for this compound.

Pharmacology
MechanismMitochondrial-derived peptide; AMPK activation / metabolic regulation
RouteSubcutaneous injection (research use)
Half-life—
Time to peak—
Duration—
Extraction confidence0.50
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 20, 2026. How this works →
Research stats
Total studies29
Human / animal / cellular8 / 16 / 1
Highest trial phasePreclinical
Years covered2010–2026
Latest study28d ago
Publication history
20102026
Research funding
410,430 NIH projects · $23.2M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

29 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
MOTS-c in sepsis-induced cardiomyopathy: Mechanisms and translational potential.
TakeawayMOTS-c may have potential relevance in sepsis-induced cardiomyopathy, but more direct evidence is needed to validate its role.
review2026Full text read0.70
Unusual aspect of cuticular morphology in human pulmonary dirofilariasis.
FindingNot reported in abstract.
Human2026Full text read0.80
First detection of a Haemoproteus macrovacuolatus-like parasite in two captive birds of the order Anseriformes: Evidence of atypical morphology.
Finding100% similarity to Haemoproteus macrovacuolatus based on a 478 bp fragment.
Animal2026Full text read0.80
Effects of F/2 medium variations on parasitic green microalgae Coccomyxa parasitica: Short-term morphofunctional adaptations.
Finding60% increase in cell density in 2F medium within 48 h.
In vitro2026Full text read0.80
Issues of species identification within Paramphistomoidea Fischoeder, 1911 (Trematoda).
FindingNot reported in abstract.
—2026Full text read0.70
Trojan horse-inspired vaccine-like nanoparticle with enhanced lubrication and active-passive synergistic anti-inflammation for post-traumatic osteoarthritis treatment.
FindingOARSI score reduced by more than 80% in a 4-week rat PTOA model.
Animal2026Full text read0.70
Tubuloside A mitigates sepsis-induced splenic injury in mice by suppressing NOX4-associated oxidative stress, inflammation, apoptosis, and mitochondrial dysfunction.
FindingTA significantly alleviated splenic injury and improved survival in septic mice.
Animal2026Full text read0.80
Kunkui Baoshen Granule attenuates diabetic kidney disease via the SIRT3/FOXO3a signaling pathway: An integrated multi-omics analysis.
FindingNot reported in abstract.
Animal2026Full text read0.80
San-Wei-Du-Juan formula ameliorates hypoxic lung injury by regulating the MAPK signaling pathway.
Finding32.5% reduction in lung wet/dry weight.
Animal2026Full text read0.80
Guizhi Wuling Decoction alleviates myocardial fibrosis by restoring mitochondrial homeostasis: Evidence from network pharmacology, molecular docking, and multi-omics integration.
FindingNot reported in abstract.
Animal2026Full text read0.70
Polydatin improves mitochondrial dynamics dysrhythmia by regulating BMAL1 to prevent and treat metabolic dysfunction-associated fatty liver disease.
FindingNot reported in abstract.
Animal2026Full text read0.70
Mailuo Shutong pills alleviate limb swelling in femoral fracture rats by orchestrating mitophagic clearance and ferroptotic suppression.
FindingNot reported in abstract.
Animal2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching MOTS-C will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much MOTS-C is discussed should be drawn from it.

Articles mentioning MOTS-C